Publishing date: Apr 07, 2021 • 4 days ago • 2 minute read •
Article content
BERLIN/ZURICH Instances of a very rare clotting condition in women aged under 60 who received AstraZeneca’s COVID-19 vaccine were 20 times higher than would normally be expected, Christian Bogdan, a member of Germany’s vaccine committee, said on Wednesday.
His comments came as the European Medicines Agency (EMA) and Britain’s medical regulator acknowledged a possible link between the AstraZeneca vaccine to rare blood clots with low blood platelet counts. The EMA conducted an in-depth review of 86 cases, including 18 fatalities.
We apologize, but this video has failed to load.
Try refreshing your browser, or
WHAT IF I HAD TELL-TALE SYMPTOMS OF A CLOT THE FIRST TIME ROUND?
Brits who suffered flu-like symptoms after getting the first jab which are common side effects of any vaccine do not need to worry, experts say.
Instead, only people who were actually diagnosed with a blood clot after getting the first dose should hold off on getting their booster shot.
In its guidance today, the JCVI said the clots appear to be an idiosyncratic reaction on first exposure to AstraZeneca s vaccine.
There have been no recorded blood clots after a second dose - all 79 thrombocytopenia have been after first doses.
Women under 60 face higher risk of rare clotting after AstraZeneca shot - German official reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
Oxford University has today paused trials of its coronavirus vaccine in children while regulators probe the jab s link to rare blood clots.
A spokesperson for the prestigious university said the move was precautionary and that there were no health issues among any of the youngsters involved in the trial.
Oxford began studying the vaccine in five-to-17-year-olds in February, with the aim of eventually scaling up the trial and testing it in 200 people.
But scientists have stopped recruiting new volunteers and it is not clear how many children have already been given a dose.
Oxford is waiting for more information from the UK s regulator, the Medicines and Healthcare products Regulatory Agency, before restarting the study, the Wall Street Journal reported.
Professor Linda Bauld of Edinburgh University said there is no evidence that the uptake of AstraZeneca jab is slowing in the UK
There is no evidence that the uptake of AstraZeneca jab is slowing in the UK despite European countries pausing their rollout of the company s vaccine, a public health expert has claimed.
Professor Linda Bauld of Edinburgh University said all studies indicated the jab was safe and effective, while the fact different countries were reviewing their position was a sign that the system was working.
Germany has suspended use of the AstraZeneca vaccine for people aged under 60 due to fears of a link with rare blood clots.